EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access

Safety and Efficacy of Avacopan in Patients with Complement 3 Glomerulopathy

Andrew S Bomback iD, Leal C Herlitz iD, Priyanka Punit Kedia, Jeffrey Petersen iD, Huibin Yue, Richard A Lafayette iD, ACCOLADE Study Group

Journal of the American Society of Nephrology · 2025

DOI: 10.1681/asn.0000000526 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of the American Society of Nephrology, 2025. Verfasst von Andrew S Bomback und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, Columbia University Irving Medical Center, New York, New York. Hauptthemen laut MEDLINE: Complement C3, Glomerulonephritis, Glomerulonephritis, Membranoproliferative. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: FDA HHS, ChemoCentryx (Wholly-owned subsidiary of Amgen), FDA's Office of Orphan Products Development, ChemoCentryx.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Key Points ACCOLADE was the first randomized trial in patients with complement 3 glomerulopathy investigating the use of avacopan, a complement component 5a receptor blocker. The trial did not meet its primary end point of change in disease activity index from baseline to 26 weeks. No new safety signals were reported; the results suggest a potential role of avacopan in milder forms of complement 3 glomerulopathy.

Background

Complement 3 (C3) glomerulopathy is a rare autoimmune disorder characterized by activation of the alternative complement pathway with isolated or dominant complement 3 deposition in glomeruli. Patients with C3 glomerulopathy may develop progressive deterioration in kidney function and kidney failure.

Methods

We studied the safety and efficacy of avacopan 30 mg twice daily in patients with C3 glomerulopathy ( N =57) with elevated (>244 ng/ml) and normal (≤244 ng/ml) levels of membrane attack complex or terminal complement complex (C5b-9) in a randomized, double-blind, placebo-controlled, phase 2 trial, with kidney biopsies performed prerandomization and at 26 and 52 weeks. The primary outcome was the percent change from baseline to week 26 in C3 Glomerulopathy Histological Index for disease activity.

Results

The study was conducted in patients with C3 glomerulopathy, including C3 GN and dense deposit disease. The median study duration was 60.0 weeks (interquartile range, 59.9–61.0). There were no significant differences in the primary outcome between the avacopan and the placebo group—least squares mean treatment difference (95% confidence interval)= −0.0 (−1.9 to 1.8). The secondary measures of efficacy including C3 Glomerulopathy Histological Index for disease chronicity, urine protein:creatinine ratio, and eGFR were not different between treatment groups. The overall incidence and type of adverse events for both treatment groups were comparable. No deaths were reported during the study, and no new safety signals were detected.

Conclusions

The primary end point for the study was not met; other clinical effects of avacopan to improve certain key kidney function parameters and slow disease progression were variable and require further evaluation. Clinical Trial registry name and registration number: Controlled Trial Evaluating Avacopan in C3 Glomerulopathy (ACCOLADE), NCT03301467.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Complement C3GlomerulonephritisGlomerulonephritis, MembranoproliferativeAdultAgedFemaleHumansMaleMiddle AgedComplement Membrane Attack ComplexDouble-Blind MethodTreatment Outcome

Substanzen

Complement C3Complement Membrane Attack Complex

Autor:innen und Institutionen

  • Division of Nephrology, Department of Medicine, Columbia University Irving Medical Center, New York, New York.
  • Department of Anatomic Pathology, Cleveland Clinic, Cleveland, Ohio.
  • Amgen, Thousand Oaks, California.
  • Stanford University Medical Center, Stanford, California.

ORCID-Profile: Andrew S Bomback, Leal C Herlitz, Jeffrey Petersen, Richard A Lafayette

Förderung

  • FDA HHS
  • ChemoCentryx (Wholly-owned subsidiary of Amgen), FDA's Office of Orphan Products Development
  • ChemoCentryx
  • FDA’s Office of Orphan Products Development

Zitieren

APA

Bomback, A. S., Herlitz, L. C., Kedia, P. P., Petersen, J., Yue, H., Lafayette, R. A., & ACCOLADE Study Group (2025). Safety and Efficacy of Avacopan in Patients with Complement 3 Glomerulopathy. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.0000000526

Vancouver

Bomback AS, Herlitz LC, Kedia PP, Petersen J, Yue H, Lafayette RA, et al. Safety and Efficacy of Avacopan in Patients with Complement 3 Glomerulopathy. Journal of the American Society of Nephrology. 2025. doi:10.1681/asn.0000000526

BibTeX
@article{Bomback2025,
  author = {Bomback, Andrew S and Herlitz, Leal C and Kedia, Priyanka Punit and Petersen, Jeffrey and Yue, Huibin and Lafayette, Richard A and ACCOLADE Study Group, ACCOLADE Study Group},
  title = {Safety and Efficacy of Avacopan in Patients with Complement 3 Glomerulopathy},
  journal = {Journal of the American Society of Nephrology},
  year = {2025},
  doi = {10.1681/asn.0000000526}
}
Kostenlos starten →